Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya

Similar documents
Dr. Collins Tabu 24 th April 2018 Nairobi, Kenya

Sudan EPI Benefits From Polio Eradication Program

MenA vaccine Introduction Country Experience, Ethiopia

HPV Vaccine Lessons Learned & New Ways Forward

Government of Bangladesh

10 th Annual African Vaccinology Course (AAVC) Cape Town 10 November 2014

Gavi s strategic framework 22 June 2016

Immunization Manual for Health Workers

Year: 2017 Volume:5 Issue-1 Introduction of newer vaccines in Immunization Programme of India: Challenges to be addressed

Expanded Programme on Immunization

GAVI S VACCINE INVESTMENT STRATEGY

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance

ffect of Health workers Strike on mmunization in Kenya

FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department

Global landscape analysis and literature review of 2 nd Year of Life immunization platform

Update from GAVI Aurelia Nguyen

VACCINE MARKETS OVERVIEW SESSION

An aggressive approach for measles outbreak among adolescents in Barranquilla, Colombia, 2011

MCSP Mozambique Program Brief Strengthening Immunization Services

INTRODUCTION Maternal Mortality and Magnitude of the problem

USAID Progress: The U.S. National Vaccine Plan of 1994

Maternal and Neonatal Tetanus Elimination by Yes, We Can! Global Immunization Meeting 18 th February 2009

Challenges of building a new vaccine delivery platform for LMICs

WHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.

Update on Meningococcal A Vaccine Development and Introduction

The Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health

Overview of Measlescontaining. through UNICEF. Overview of [VACCINE] through UNICEF

Ensuring the quality of polio outbreak response activities: A rationale and guide for 3 month, quarterly and 6 month independent assessments

Vaccines. Global impact of a preventive technology. Edwin J. Asturias, MD

Report on MCSP Support for the Polio Switch in April 2016

TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE

How does Gavi make vaccine investment decisions?

3. CONCLUSIONS AND RECOMMENDATIONS

Maternal Newborn and Child Health

Global Health Policy: Vaccines

Polio and measles control: opportunities and threats for health systems

The role of the health system in uptake of the Human Papilloma-virus (HPV) vaccine among adolescents 9-15 years in Mbale district, Eastern Uganda

Expanded Programme on Immunization (EPI):

Report. 10 th Meeting of the Expert Review Committee (ERC) on Polio Eradication in Nigeria

Midterm Review of the Global Measles and Rubella Strategic Plan W. A. Orenstein, MD SAGE Geneva, 19 October 2016

Towards the Achievement of GHSA 2024 s Overarching Targets

Humanitarian Situation Report Horn of Africa Measles Outbreak Response

achievements, challenges and financing

Together we can attain health for all

Ex post evaluation Tanzania

Expanded Programme on Immunization

In the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.

The power of partnership: the GAVI Alliance Board

Global Health Policy: Vaccines

Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018

IMMUNISATION CHALLENGES IN FIJI AND THE PACIFIC. 10th New Zealand Immunization Conference Litiana Volavola, National EPI Programme Officer, Fiji

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines

2016 NON FINANCIAL RESOURCE REQUIREMENTS GPEI DONOR CONTRIBUTIONS

Expanded Programme on Immunization (EPI)

FY2017 Q1: CORE Group Polio Project (CGPP) Quarterly Update

Expanded Programme on Immunization (EPI)

Perspectives on Ensuring Access to Vaccines in Lower Income Countries

Progress in maternal and child health: Uzbekistan and WHO European Region

Expanded Programme on Immunization (EPI)

Progress reports on selected Regional Committee resolutions:

Update on Status of Wild Poliovirus Outbreak in Kenya. 9 th Meeting of the IMB 1-3 October 2013 London, UK

Vaccines. Global impact of a preventive technology. Edwin J. Asturias, MD

Improving the vaccine supply chain in developing countries via increasing freeze protected cold chain equipment. October, 2014

used for HPV vaccine delivery to identify best practices and inform efforts to improve HPV vaccine coverage nationwide.

Cholera Epidemiological study in the East and Southern Africa region UNICEF ESARO study

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

CLOSING MR IMMUNITY GAPS EXPERIENCES FROM THE REGIONS MALAWI. Geoffrey Zimkambani Chirwa EPI Manager

Selected vaccine introduction status into routine immunization

GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS

Countdown to 2015: tracking progress, fostering accountability

FIMDP 2013 DEPT OF COMMUNITY MEDICINE SRM MEDICAL COLLEGE,SRM UNIVERSITY & UNSW AUSTRALIA 9 TH & 10 TH JAN 2013

Gavi Alliance Strategy : Goal level indicators and disease dashboard

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision

Copenhagen, Denmark, September August Malaria

HOA Outbreak Response assessment. Kenya 8 th to 12 th June 2015

YELLOW FEVER UPDATE. DPGH Meeting Dr. Grace Saguti NPO/DPC 13 July 2016

EXPANDED PROGRAM ON IMMUNIZATION (EPI)

Immunization Update & focus on meningococcal vaccine PART 1

Partnership That Gives Dividends.

SPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA. 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m.

~Health and Development Initiative~

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007

HEALTH CLUSTER. Summary Report. Prioritization of woredas for the drought related emergency health response. Dereje Ayana 2/22/2016

Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.

Expanded Programme on Immunization (EPI)

Baby Friendly Vaccines

NO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL. Measles & Rubella Campaigns

Programme Bulletin Policy updates and vaccine information for GAVI countries and partners

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

Vaccination program: governance and policy decision process in Malaysia DR SAFURAH JA AFAR MINISTRY OF HEALTH MALAYSIA

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

CONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN

Integrated Disease Surveillance and Response Bulletin INTEGRATED DISEASE SURVEILLANCE AND RESPONSE BULLETIN

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016

Transcription:

Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya

Presentation Outline Background Immunization Performance review Available Opportunities for engagement Planned and ongoing strategies- New Vaccines and Technologies Other Key priorities

Immunization & Disease Once your immune system is trained to resist a disease, you are said to be immune to it Before vaccines, the only way to become immune to a disease was to actually get it and.with luck, survive it With naturally acquired immunity..you suffer the disease & risk the complications,..can be quite serious or even deadly You may be contagious and pass the disease to family members, friends, or others who come into contact with you Diseases have been able to circumvent drugs through development of resistance but this is yet to be reported for vaccination Vaccines are key in protecting our mainstay drugs from resistance

Immunization in the developing world Developing countries represent about 75 million surviving infants (55% of worlds birth cohort) Every year, millions of children in poor countries die from preventable diseases because they do not have access to life-saving vaccines. Possible reasons: Existing vaccines being either too expensive Existing vaccines not optimal for developing country use Vaccine development has high fixed costs and manufacturers have historically not seen value in investing in new products for developing country needs Increase in Missed Opportunities for vaccination: Economic barriers- Charging for vaccination Failure to check for children s vaccination status diuring treatment

Evolution of Immunization in Kenya Established in 1980, initially provided on an ad-hoc basis through primary schools and the larger health institutions and facilities Initial Government focus was on establishing & strengthening the health service delivery, subsequently achieving Universal Child Immunization goals of immunizing at least 80% of the target population in 1990 s Program focus shifted to disease control, elimination and eradication: Maternal Neonatal Tetanus Elimination Measles/ Rubella Elimination Polio Eradication Guiding Principles: Constitution of Kenya, Kenya Health Policy 2014-2030, Kenya Health Sector Strategic and Investment Plan 2014-2017, National Policy on Immunization 2014, Global Vaccine Action Plan 2011-2020, KENITAG

Evolution of Immunization in Kenya 1978 Alma Ata Declaration by WHA 1980 KEPI established, target 6 childhood killer diseases 2006 All vaccination services under DVI 2002 Pentavalent New Vaccine Introductions 2011 PCV 10 2013 Measles 2 nd dose 2014 Rota Virus 2015 IPV 2016 Switched from Measles-only to Measles-Rubella 2019 HPV (girls 10 yrs) 1980 - present MOH continues to improve, expand and intensify immunization services in Kenya.

10

Available opportunities for practitioners Operational level and Mid level managers training Review of guidelines and development of SOPs for vaccine management, reporting and communication Improved temperature monitoring systems Routine IEC materials and minimal messaging on routine immunization Support research work and other evidence generating activities Cold chain equipment support for private high volume health facilities Supply of vaccines and injection devices

so how about new vaccine introduction?

Considerations we make in the choice of a an Immunization Intervention Magnitude of public health problem conclusively determined Risk groups clearly identified Ensured Sustainable availability of an effective vaccine Ability of vaccination services to cover > 80% of at-risk-population in order to break transmission Political Goodwill Cost effectiveness International Trends, Quality approval and Monitoring OR Targeting of only very high-risk groups e.g. Health workers; prisoners; food handlers 15

Operations of the EPI system Vaccine Supply & Quality Logistics Service delivery Surveillance Advocacy & Communication

New Vaccine and Technologies Introduction Updates HPV introduction into routine immunization schedule in 2019 Scale up of Yellow Fever vaccine to West Pokot and Turkana- 2018 Meningitis A vaccination campaign and subsequent introduction- National Switch from Two to Four dose Pneumococcal vaccine formulation Switch from TT to Td- 2018 Malaria pilot project Electronic and Remote Temperature Monitoring Devices 17

Malaria Vaccine WHO published a policy position for the first malaria vaccine (RTSS) in January 2016 Recommended pilot introduction be done in sub Sahara Africa in distinct settings Further evaluation of implementability of a four dose schedule Further evaluation of impact Kenya is one of the three countries that applied to participate in the pilot implementation The objective is to reduce mortality and morbidity in children in combination with the existing prevention strategies Selection of pilot implementation areas based on criteria such as malaria parasite prevalence Implementation planned for July 2018

Map of the selected MVIP areas

Vaccination Strategy The MVIP will be fully integrated in the routine vaccination program Main strategy is will be use of fixed posts- All current vaccinating health facilities Outreaches or mobile vaccinations will be carried out where necessary in areas that access and utilization is a challenge Existing malaria control strategies are integrated with vaccination delivery.

Proposed Immunization Schedule Age 6months 7months 9months 24months Proposed schedule Other interventions Vit A MR1st Dose Vit A, Deworming

HPV Vaccine HPV Vaccine Demonstration project conducted in Kitui County (2013-2015) School based approach used Coverage of 96% Resource intensive Nationwide introduction planned for 2019 Facility based approach Supplemented with school outreach, community outreach (as per county needs) Sustainable and less expensive than school based approach( reduced personnel and transport costs) Needs intensive advocacy and mobilisation efforts to achieve required coverage Status: Support for introduction approved, Delays due to vaccine supply challnges

Health based, with outreach services Vaccination Strategy Modeled on and integrated with routine immunization delivery Same target- Standard 4 class in school going children, in both public and private primary schools- proxy for 10 year olds Schools and education system a key pillar for mobilization, List by district and Zone to generated Vaccination in schools could be organized as part of outreach- Efficiency, Closer engagement with health teams from the health facilities Vaccination card given to girls and documentation summary retained at the Health Facility

Meningitis & Yellow fever The regional Immunization plan recommends Countries within meningitis belt to implement strategies to control Meningitis Countries at risk of Yellow fever to implement strategies to control Yellow fever Kenya is part of the meningitis belt, outbreaks experienced in the past A 2016 Meningitis risk assessment recommended introduction of the vaccine in a one phase campaign in high risk areas (Counties bordering Uganda, South Sudan and Ethiopia) MOH plans to conduct a Menengitis campaign for Individuals 1-29 years, with subséquent introduction into routine immunization Yellow fever vaccine is currently administered in 2 counties( Baringo, Elgeyo Marakwet) A 2015 Yellow Fever risk assessment recommended expanding to include Turkana & West Pokot Counties- Planned for 2018

Introduction of Men-Afrivac Vaccine through Vaccination campaign in Kenya Areas for vaccination

New Vaccine Introduction- The Clinical setting Introduction of key vaccines against severe childhood diseases As global coverage of new vaccines expands, principal etiological causes of childhood disease are largely controlled by immunization Clinical case definitions Clinical Case management of diseases Possible Increase in Diversity of cases Implications in HIV Infection? Significant reduction in rates of severe disease, more non-communicable disease Influence of reduction these diseases on the clinical diagnosis, classification, management, and control Programmatic implications of new vaccine introduction- Any changes to accommodate new vaccine?

Immunization and Saving lives is our shared responsibility. Always Remember EVERY CHILD COUNTS!

28